[go: up one dir, main page]

CN109311908A - 作为Akt抑制剂的二氢吡唑氮杂卓类化合物 - Google Patents

作为Akt抑制剂的二氢吡唑氮杂卓类化合物 Download PDF

Info

Publication number
CN109311908A
CN109311908A CN201780037686.3A CN201780037686A CN109311908A CN 109311908 A CN109311908 A CN 109311908A CN 201780037686 A CN201780037686 A CN 201780037686A CN 109311908 A CN109311908 A CN 109311908A
Authority
CN
China
Prior art keywords
milligrams
lcms
esi
milliliters
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780037686.3A
Other languages
English (en)
Other versions
CN109311908B (zh
Inventor
卢伦
张志博
李刚
胡利红
丁照中
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin Zhenbao Pharmaceutical Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109311908A publication Critical patent/CN109311908A/zh
Application granted granted Critical
Publication of CN109311908B publication Critical patent/CN109311908B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

提供一种作为Akt抑制剂的二氢吡唑氮杂卓类化合物，具体公开了式(I)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201780037686.3A 2016-06-16 2017-06-13 作为Akt抑制剂的二氢吡唑氮杂卓类化合物 Active CN109311908B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610428049 2016-06-16
CN2016104280496 2016-06-16
CN201610674021 2016-08-15
CN2016106740210 2016-08-15
PCT/CN2017/088030 WO2017215588A1 (zh) 2016-06-16 2017-06-13 作为Akt抑制剂的二氢吡唑氮杂卓类化合物

Publications (2)

Publication Number Publication Date
CN109311908A true CN109311908A (zh) 2019-02-05
CN109311908B CN109311908B (zh) 2021-05-07

Family

ID=60663995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780037686.3A Active CN109311908B (zh) 2016-06-16 2017-06-13 作为Akt抑制剂的二氢吡唑氮杂卓类化合物

Country Status (6)

Country Link
US (1) US10654868B2 (zh)
EP (1) EP3473628B1 (zh)
JP (1) JP6900406B2 (zh)
KR (1) KR102351270B1 (zh)
CN (1) CN109311908B (zh)
WO (1) WO2017215588A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111433213A (zh) * 2017-12-13 2020-07-17 哈尔滨珍宝制药有限公司 作为Akt抑制剂的盐型及其晶型

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022121788A1 (zh) * 2020-12-07 2022-06-16 南京正大天晴制药有限公司 一种吡唑并氮杂卓类akt抑制剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1639151A (zh) * 2002-03-12 2005-07-13 霍夫曼-拉罗奇有限公司 新的氮杂环庚烷衍生物
CN101094833A (zh) * 2004-07-12 2007-12-26 伊邓药品公司 四肽类似物
WO2008065054A1 (en) * 2006-11-28 2008-06-05 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
WO2008098104A1 (en) * 2007-02-07 2008-08-14 Smithkline Beecham Corporation Inhibitors of akt activity
EP2002836A1 (en) * 2007-05-31 2008-12-17 Nerviano Medical Sciences S.r.l. Cyclocondensed azaindoles active as kinase inhibitors
WO2009089305A1 (en) * 2008-01-07 2009-07-16 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
CN103298461A (zh) * 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129455A1 (en) 2008-06-26 2011-06-02 Hong Lin Inhibitors of akt activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1639151A (zh) * 2002-03-12 2005-07-13 霍夫曼-拉罗奇有限公司 新的氮杂环庚烷衍生物
CN101094833A (zh) * 2004-07-12 2007-12-26 伊邓药品公司 四肽类似物
WO2008065054A1 (en) * 2006-11-28 2008-06-05 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
WO2008098104A1 (en) * 2007-02-07 2008-08-14 Smithkline Beecham Corporation Inhibitors of akt activity
EP2002836A1 (en) * 2007-05-31 2008-12-17 Nerviano Medical Sciences S.r.l. Cyclocondensed azaindoles active as kinase inhibitors
WO2009089305A1 (en) * 2008-01-07 2009-07-16 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
CN103298461A (zh) * 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111433213A (zh) * 2017-12-13 2020-07-17 哈尔滨珍宝制药有限公司 作为Akt抑制剂的盐型及其晶型
CN111433213B (zh) * 2017-12-13 2023-03-10 哈尔滨珍宝制药有限公司 作为Akt抑制剂的盐型及其晶型

Also Published As

Publication number Publication date
US20190233434A1 (en) 2019-08-01
KR102351270B1 (ko) 2022-01-14
CN109311908B (zh) 2021-05-07
US10654868B2 (en) 2020-05-19
WO2017215588A1 (zh) 2017-12-21
EP3473628B1 (en) 2019-12-11
EP3473628A4 (en) 2019-05-01
JP6900406B2 (ja) 2021-07-07
KR20190017996A (ko) 2019-02-20
JP2019518052A (ja) 2019-06-27
EP3473628A1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
KR102615733B1 (ko) 항암제로서의 치환 2-h-피라졸 유도체
JP6802251B2 (ja) 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン
EP3080100B1 (en) Inhibitors of lysine specific demethylase-1
CN112055709A (zh) 吡嗪化合物和其用途
CN107531695A (zh) Jak抑制剂
CN106661056B (zh) 作为酪蛋白激酶1δ/ε抑制剂的咪唑并哒嗪衍生物
CN108349977A (zh) Jak抑制剂
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN110062758A (zh) 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物
EP3060563A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
EP2678315B1 (en) (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR
CN108659005A (zh) 作为egfr抑制剂的喹唑啉衍生物
AU2013212175A1 (en) Azaheterocyclic compounds
CN107922349A (zh) 作为fgfr和vegfr抑制剂的乙烯基化合物
EP3971190A1 (en) Heterocycle-fused pyrimidine derivative and use thereof
CN111683928A (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
CN116888108A (zh) 新型egfr降解剂
EP4079734A1 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
Guerrini et al. Synthesis and pharmacological evaluation of pyrazolo [1, 5-a] pyrimidin-7 (4H)-one derivatives as potential GABAA-R ligands
CN107709323A (zh) 羟基嘌呤类化合物及其应用
CN111655689B (zh) 吡唑并吡啶酮化合物
CN109311908A (zh) 作为Akt抑制剂的二氢吡唑氮杂卓类化合物
CN107614498A (zh) 二氮杂‑苯并荧蒽类化合物
CN111747954B (zh) 吡嗪化合物和其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 210032 Jiangsu city of Nanjing province Nanjing high tech Development Zone of High Road No. 9 business office building room 218

Applicant before: MEDSHINE DISCOVERY Inc.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20190816

Address after: 150060 Yantai No. 8 Pharmaceutical Research Institute, Harbin Development Zone, Heilongjiang Province

Applicant after: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant